225 related articles for article (PubMed ID: 9520961)
1. Assessing the value of a new pharmaceutical. A feasibility study of contingent valuation in managed care.
O'Brien BJ; Goeree R; Gafni A; Torrance GW; Pauly MV; Erder H; Rusthoven J; Weeks J; Cahill M; LaMont B
Med Care; 1998 Mar; 36(3):370-84. PubMed ID: 9520961
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.
Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R
J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712
[TBL] [Abstract][Full Text] [Related]
4. A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.
Lyman GH
Eur J Cancer; 2000 Apr; 36 Suppl 1():S15-21. PubMed ID: 10785605
[TBL] [Abstract][Full Text] [Related]
5. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R
Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
[TBL] [Abstract][Full Text] [Related]
7. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
8. Health care outcomes case study: Febrile neutropenia.
Holdsworth MT; Duncan MH
Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S15-8. PubMed ID: 8846241
[TBL] [Abstract][Full Text] [Related]
9. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.
Frampton JE; Faulds D
Pharmacoeconomics; 1996 Jan; 9(1):76-96. PubMed ID: 10161371
[TBL] [Abstract][Full Text] [Related]
10. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
[TBL] [Abstract][Full Text] [Related]
11. Individual responsibility and health-risk behaviour: a contingent valuation study from the ex ante societal perspective.
van der Star SM; van den Berg B
Health Policy; 2011 Aug; 101(3):300-11. PubMed ID: 21168930
[TBL] [Abstract][Full Text] [Related]
12. Estimating Willingness to Pay for an Improved Service Delivery to Patients Referring Namazi Hospital Chemical Therapy Ward in Iran Using Contingent Valuation.
Kavosi Z; Jafari A; Keshtkaran V; Pourahmadi E
Asian Pac J Cancer Prev; 2018 Jul; 19(7):1817-1823. PubMed ID: 30049193
[TBL] [Abstract][Full Text] [Related]
13. Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors.
Johnson P; Bancroft T; Barron R; Legg J; Li X; Watson H; Naeim A; Watkins A; Marshall DA
Value Health; 2014 Jun; 17(4):380-9. PubMed ID: 24968998
[TBL] [Abstract][Full Text] [Related]
14. Willingness to pay for voluntary community-based health insurance: findings from an exploratory study in the state of Penang, Malaysia.
Shafie AA; Hassali MA
Soc Sci Med; 2013 Nov; 96():272-6. PubMed ID: 23528670
[TBL] [Abstract][Full Text] [Related]
15. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.
Glaspy JA; Bleecker G; Crawford J; Stoller R; Strauss M
Eur J Cancer; 1993; 29A Suppl 7():S23-30. PubMed ID: 7508727
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
17. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
[TBL] [Abstract][Full Text] [Related]
18. Willingness to participate and Pay for a proposed national health insurance in St. Vincent and the grenadines: a cross-sectional contingent valuation approach.
Adams R; Chou YJ; Pu C
BMC Health Serv Res; 2015 Apr; 15():148. PubMed ID: 25890181
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
20. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.
Rofail P; Tadros M; Ywakim R; Tadrous M; Krug A; Cosler LE
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):699-709. PubMed ID: 23252353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]